Epigenetic modification restores functional PR expression in endometrial cancer cells

Current Pharmaceutical Design

Volumn 20, Issue 11, 2014, Pages 1874-1880

  Yang, Shujie ^a,b   Xiao, Xue ^a   Jia, Yichen ^a   Liu, Xiaoyue ^a   Zhang, Yuping ^a   Wang, Xinjun ^a   Winters, Christopher J ^a   Devor, Eric J ^a   Meng, Xiangbing ^a,b   Thiel, Kristina W ^a   Leslie, Kimberly K ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Cell cycle arrest; Endometrial cancer; Epigenetic modulation; HDAC inhibitor; PRE containing genes; Progesterone; Progesterone receptor

Indexed keywords

CYCLIN D1; MESSENGER RNA; PANOBINOSTAT; PROGESTERONE RECEPTOR; PROTEIN P21; PROTEIN P27; TRANSCRIPTION FACTOR FKHR; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; INDOLE DERIVATIVE; PROGESTERONE;

ARTICLE; DOSE RESPONSE; ENDOMETRIAL CANCER CELL LINE; EPIGENETICS; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; STABLE EXPRESSION; WESTERN BLOTTING; DOWN REGULATION; DRUG EFFECTS; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; TUMOR CELL LINE; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENDOMETRIAL NEOPLASMS; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; PROGESTERONE; RECEPTORS, PROGESTERONE; RNA, MESSENGER; UP-REGULATION;

EID: 84901853685     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990532     Document Type: Article

References (13)

1. Cancer Facts and Figures American Cancer Society 2011 November 21, 2011; Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-029771.pdf.
2. Yang S, Thiel KW, Leslie KK. Progesterone: the ultimate endometrial tumor suppressor. Trends Endocrinol Metab 2011; 22(4): 145-52.
3. Mortel R, Zaino R, Satyaswaroop PG. Heterogeneity and progesterone-receptor distribution in endometrial adenocarcinoma. Cancer 1984; 53(1): 113-6.
4. Yang S, Thiel KW, De Geest K, Leslie KK. Endometrial cancer: reviving progesterone therapy in the molecular age. Discov Med 2011; 12(64): 205-12.
5. Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999; 17(6): 1736-44.
6. Sasaki M, Dharia A, Oh BR, Tanaka Y, Fujimoto S, Dahiya R. Progesterone receptor B gene inactivation and CpG hypermethylation in human uterine endometrial cancer. Cancer Res 2001; 61(1): 97-102.
7. Xiong Y, Dowdy SC, Gonzalez Bosquet J, et al. Epigeneticmediated upregulation of progesterone receptor B gene in endometrial cancer cell lines. Gynecol Oncol 2005; 99(1): 135-41.
8. Ren Y, Liu X, Ma D, Feng Y, Zhong N. Down-regulation of the progesterone receptor by the methylation of progesterone receptor gene in endometrial cancer cells. Cancer Genet Cytogenet 2007; 175(2): 107-16.
9. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25(4): 402-8.
10. Lange CA, Shen T, Horwitz KB. Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc Natl Acad Sci USA 2000; 97(3): 1032-7.
11. Leslie KK, Stein MP, Kumar NS, et al. Progesterone receptor isoform identification and subcellular localization in endometrial cancer. Gynecol Oncol 2005; 96(1): 32-41.
12. Bantscheff M, Hopf C, Savitski MM, et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nature Biotechnol 2011; 29(3): 255-65.
13. Meng X, Brachova P, Yang S, et al. Knockdown of MTDH sensitizes endometrial cancer cells to cell death induction by death receptor ligand TRAIL and HDAC inhibitor LBH589 co-treatment. PLoS One 2011; 6(6): e20920.